Analysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/28/21
How The Future Looks For Last Week's Biggest Losers: Futu, Regulus Therapeutics And MoreBenzinga • 10/18/21
Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney DiseasePRNewsWire • 10/12/21
Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical SciencePRNewsWire • 09/30/21
Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferencePRNewsWire • 09/09/21
Regulus Therapeutics' (RGLS) CEO Jay Hagan on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/11/21
Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent UpdatesPRNewsWire • 08/10/21
Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference CallPRNewsWire • 08/03/21
Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021PRNewsWire • 06/25/21
Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021PRNewsWire • 06/21/21
Do Options Traders Know Something About Regulus Therapeutics (RGLS) Stock We Don't?Zacks Investment Research • 06/11/21
Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) ProgramPRNewsWire • 05/21/21
Regulus Therapeutics Inc. (RGLS) CEO Jay Hagan on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21